{"filing":{"accession_number":"0001517022-26-000050","cik":"0001517022","ticker":"AKBA","company_name":"Akebia Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"akba-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/akba-20260805.htm"},"events":[{"id":24891,"run_id":22566,"accession_number":"0001517022-26-000050","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Akebia's second quarter 2026 financial results, including total revenues of $49.1 million, Vafseo net product revenues of $21.3 million (34% increase over Q1), and a net loss of $8.9 million. The press release, furnished as Exhibit 99.1, is the standard format for quarterly earnings disclosure under Item 2.02 and includes detailed financial metrics, business highlights, and forward-looking statements typical of earnings announcements.","company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25583,"accession_number":"0001517022-26-000050","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Akebia's second quarter 2026 financial results, including total revenues of $49.1 million, Vafseo net product revenues of $21.3 million (34% increase over Q1), and a net loss of $8.9 million. The press release, furnished as Exhibit 99.1, is the standard format for quarterly earnings disclosure under Item 2.02 and includes detailed financial metrics, business highlights, and forward-looking statements typical of earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:33:04.351394+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25583,"accession_number":"0001517022-26-000050","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Akebia's second quarter 2026 financial results, including total revenues of $49.1 million, Vafseo net product revenues of $21.3 million (34% increase over Q1), and a net loss of $8.9 million. The press release, furnished as Exhibit 99.1, is the standard format for quarterly earnings disclosure under Item 2.02 and includes detailed financial metrics, business highlights, and forward-looking statements typical of earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:33:04.351394+00:00","company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","filing_date":"2026-08-05"}]}